The Cardiometabolic Health Congress is leading the fight against cardiometabolic disease through dynamic medical education. Lead by the industry’s top experts, CMHC brings together evidence-based medicine, education rooted in adult learning principles, and innovative techniques to positively impact the healthcare community.

**CMHC**: Advancing the Fight Against Cardiometabolic Disease.
Educational Experience

Live, In-Person
Annual conferences, meetings, and symposia.

Innovative Online
Interactive and engaging education for the HCP.

Print & Resources
Journal publications; clinician and patient resources.

Outcomes Measurement
Engaging outcomes reports analyzing the impact of the education.
CMHC Chairs & Senior Planning Committee

Robert H. Eckel, MD
Christie M. Ballantyne, MD
George L. Bakris, MD
Anne L. Peters, MD
Pamela B. Morris, MD
Deepak L. Bhatt, MD, MPH
Clyde W. Yancy, MD, MSc, MACP
Keith C. Ferdinand, MD, FACC, FAHA
Live Experience

- Annual Conferences
- Satellite Symposia
- Live Infographic Activities
- Live Case Simulation
- Flipped Classroom
- Workshops
- Live Webinars/Webcasts
Digital Experience

- Interactive Infographic
- Case Simulation
- Digital Highlights
- Video Animations
- Resources
- Social Media Campaigns
- Patient Perspectives
Global Education

Live Conferences
Multi-day, live conferences held in conjunction with local societies & associations.

Satellite Symposia
Live and enduring satellite symposia held at major medical meetings around the Globe.

Online Education
Innovative online education translated and developed specifically for HCP's around the Globe.

Global Reach
Exclusive partnerships and collaborations provide targeted reach to HCP's around the Globe.
The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases of non-alcoholic fatty liver disease (NAFLD) and its most aggressive subtype, non-alcoholic steatohepatitis (NASH), are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is now the second leading cause of liver transplants in the US and poised to become the leading cause of liver transplants by 2020.

Thus, clinicians in several therapeutic areas may treat or possibly encounter patients with diagnosed or undiagnosed NASH, and being aware of this disease is crucial for the early recognition, diagnosis and management in order to improve outcomes. NASH, described as the hepatic manifestation of metabolic syndrome, remains challenging to diagnose and treat, but significant advances have been made in the recent years. This activity will discuss the increasing prevalence and clinical significance of NASH, current and emerging diagnostic methods, what can be done now to manage it, and emerging treatment options that are in advanced clinical development.
Virtual Symposium & Case Simulation

In this symposium, faculty gave an overview of the management of hypercholesterolemia to reduce the risk of adverse atherosclerotic cardiovascular disease (ASCVD) events, including how to identify patients with statin intolerance or with residual risk despite maximized statin therapy, as well as current management of elevated cholesterol with statin and non-statin therapies according to the updated guidelines. In addition, the symposium summarized the evidence on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and emerging cholesterol-lowering therapies. Challenges with access to newer therapies and appropriate resources to address this issue will also be reviewed.

During the activity, case-based, patient simulation technology was utilized to provide learners with the opportunity to explore different decision paths and get immediate feedback on their treatment decisions, allowing for enhanced competence in the individualization of therapy for patients at-risk for ASCVD.

A Patient Testimonial Video was shown to provide perspective on access to medications.
LINK: https://www.youtube.com/watch?v=RnWTVnJytA&t=3s

A downloadable RAPID REVIEW POCKET GUIDE: Guidance on Cholesterol Management was created and provided to attendees to access and refer to on their own.
LINK: https://issuu.com/tarsusmedical/docs/cmhcc_pocket-guide_0127820_issuu
OUTCOMES

Succinct educational outcomes posters developed to present the impact summary of the education.

Reports
Engaging educational outcomes measurement reports analyzing the impact of the education.

Posters
Engaging educational outcomes measurement reports analyzing the impact of the education.
The Changing Landscape of NASH: Navigating Current and Emerging Approaches in Diagnosis and Treatment

Educational Activity Outcomes Spotlight*

Launched 11/30/2019
Enduring webinar launched 11/30/19 and is live on the CMHC and myCME websites for one year.

Learners To-Date**
Activity is trending ahead with 2,728 learners and 1,368 CME completions.
84% US-based | 16% non-US-based.

Increase in Knowledge
Of participants indicated that the activity increased their knowledge surrounding the management of patients with NAFLD and NASH.

Potential Patient Impact
29,271 Patients per week will potentially be affected by this educational activity.

*Preliminary outcomes report from myCME can be found HERE.
**Data listed is current as of 8/31/2020.
Managing LDL-C to Reduce ASCVD Risk: Recent Advancements and Strategies to Optimize Patient Outcomes

Educational Activity Outcomes Spotlight

**Increase in Knowledge**
95%
Of participants agreed that their knowledge increased surrounding the management of hypercholesterolemic patients at risk for ASCVD.

**Intent to Change**
46%
Of participants intend to make changes as a result of this activity.

**Practice Reinforcement**
52%
Of participants indicated that their current practice has been reinforced by the information presented.

**Potential Patient Impact**
2,268 Patients per week will potentially be affected by this educational activity.
Collaboration is key to CMHC, which is why we partner with other organizations, accredited providers, and patient advocacy groups to offer added expertise and assist in expanding access.